All Articles
Leave no patient behind: how the FDA approval of Keytruda for specific biomarkers will put laboratory testing in the front line

Leave no patient behind: how the FDA approval of Keytruda for specific biomarkers will put laboratory testing in the front line

5 June, 2017

The recent announcement that the FDA has granted approval to Merck's Keytruda (pembrolizumab) "for a specific genetic feature (biomarker)" is leading us into a new era in which the integration of diagnostics and biomarker detection on the treatment pathway is not an option, but mandatory.|The recent announcement that the FDA has granted approval to Merck's Keytruda (pembrolizumab) "for a specific genetic feature (biomarker)" is leading us into a new era in which the integration of diagnostics and biomarker detection on the treatment pathway is not an option, but mandatory.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.